IN2014MN01372A - - Google Patents

Info

Publication number
IN2014MN01372A
IN2014MN01372A IN1372MUN2014A IN2014MN01372A IN 2014MN01372 A IN2014MN01372 A IN 2014MN01372A IN 1372MUN2014 A IN1372MUN2014 A IN 1372MUN2014A IN 2014MN01372 A IN2014MN01372 A IN 2014MN01372A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Kim Suzanne Midwood
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201121280A external-priority patent/GB201121280D0/en
Priority claimed from GBGB1214806.0A external-priority patent/GB201214806D0/en
Application filed by Isis Innovation filed Critical Isis Innovation
Publication of IN2014MN01372A publication Critical patent/IN2014MN01372A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rehabilitation Therapy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1372MUN2014 2011-12-12 2014-07-05 IN2014MN01372A (cg-RX-API-DMAC10.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201121280A GB201121280D0 (en) 2011-12-12 2011-12-12 Biomarker
GBGB1214806.0A GB201214806D0 (en) 2012-08-20 2012-08-20 Biomarker
PCT/GB2012/053104 WO2013088140A2 (en) 2011-12-12 2012-12-12 Biomarker and use thereof

Publications (1)

Publication Number Publication Date
IN2014MN01372A true IN2014MN01372A (cg-RX-API-DMAC10.html) 2015-04-17

Family

ID=47561655

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1372MUN2014 IN2014MN01372A (cg-RX-API-DMAC10.html) 2011-12-12 2014-07-05

Country Status (9)

Country Link
US (1) US20140322211A1 (cg-RX-API-DMAC10.html)
EP (1) EP2791686B1 (cg-RX-API-DMAC10.html)
JP (1) JP6158825B2 (cg-RX-API-DMAC10.html)
KR (1) KR20140109956A (cg-RX-API-DMAC10.html)
CN (1) CN104105967B (cg-RX-API-DMAC10.html)
BR (1) BR112014014295A2 (cg-RX-API-DMAC10.html)
CA (1) CA2894746A1 (cg-RX-API-DMAC10.html)
IN (1) IN2014MN01372A (cg-RX-API-DMAC10.html)
WO (1) WO2013088140A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400521D0 (en) * 2014-01-13 2014-02-26 Isis Innovation Biomarker and uses thereof
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
CN1317303C (zh) * 2002-02-26 2007-05-23 希格马托制药工业公司 抗人腱生蛋白单克隆抗体
US20060115862A1 (en) * 2004-11-17 2006-06-01 Duke University Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
KR100958840B1 (ko) * 2007-08-28 2010-05-24 단국대학교 산학협력단 항-테나신 c 펩타이드 및 그의 용도
CA2702623A1 (en) * 2007-10-22 2009-04-30 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Insti Tute For Biomedical Research Use of tenascin-w as a biomarker for colon cancer
FR2930036B1 (fr) * 2008-04-11 2010-05-07 Assist Publ Hopitaux De Paris Procede de diagnostic d'une hypertension arterielle pulmonaire.
GB0904355D0 (en) * 2009-03-13 2009-04-29 Imp Innovations Ltd Biological materials and uses thereof
BR112012025841A2 (pt) * 2010-05-12 2016-06-28 Hills Pet Nutrition Inc métodos para o diagnóstico, controle e profilaxia de inflamação e mitigação de condições inflamatórias em cães
JP5360922B2 (ja) * 2011-08-03 2013-12-04 国立大学法人山口大学 新規虚血マーカー及びこれを用いた虚血状態の検出方法

Also Published As

Publication number Publication date
CN104105967A (zh) 2014-10-15
CN104105967B (zh) 2017-03-08
JP6158825B2 (ja) 2017-07-05
CA2894746A1 (en) 2013-06-20
WO2013088140A3 (en) 2013-08-08
WO2013088140A2 (en) 2013-06-20
KR20140109956A (ko) 2014-09-16
EP2791686A2 (en) 2014-10-22
US20140322211A1 (en) 2014-10-30
JP2015503106A (ja) 2015-01-29
HK1203232A1 (en) 2015-10-23
EP2791686B1 (en) 2017-02-15
BR112014014295A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
BR112014008202A2 (cg-RX-API-DMAC10.html)
BR112013022641A2 (cg-RX-API-DMAC10.html)
BR112013031251A2 (cg-RX-API-DMAC10.html)
BR112013027245A2 (cg-RX-API-DMAC10.html)
BR112013024383A2 (cg-RX-API-DMAC10.html)
BR112013017670A2 (cg-RX-API-DMAC10.html)
BR112013027830A2 (cg-RX-API-DMAC10.html)
AP3853A (cg-RX-API-DMAC10.html)
BR112013023927A2 (cg-RX-API-DMAC10.html)
BR112013024365A2 (cg-RX-API-DMAC10.html)
BR112013028733A2 (cg-RX-API-DMAC10.html)
BR112013027121A2 (cg-RX-API-DMAC10.html)
AP2016009466A0 (cg-RX-API-DMAC10.html)
BR112013031556A2 (cg-RX-API-DMAC10.html)
BR112013032368A2 (cg-RX-API-DMAC10.html)
BR112013032377A2 (cg-RX-API-DMAC10.html)
BR112013026895A2 (cg-RX-API-DMAC10.html)
BR112013027761A2 (cg-RX-API-DMAC10.html)
BR112013021637A2 (cg-RX-API-DMAC10.html)
BR112013025487A2 (cg-RX-API-DMAC10.html)
BR112013023266A2 (cg-RX-API-DMAC10.html)
BR112013030734A2 (cg-RX-API-DMAC10.html)
BR112013017878A2 (cg-RX-API-DMAC10.html)
BR112013027657A2 (cg-RX-API-DMAC10.html)
BR112013022499A2 (cg-RX-API-DMAC10.html)